Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.115.002340 http://scihub22266oqcxt.onion/10.1161/JAHA.115.002340 C4845271!4845271!26627879     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 310.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 310.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 310.4 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26627879.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Am+Heart+Assoc 2015 ; 4 (12): ä Nephropedia Template TP {{tp|p=26627879|t=2015. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep?Vein Thrombosis as First?Line Therapy (AMPLIFY) Trial |pdf=|usr=}}{{26627879}} gab.com Text Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First Line Therapy (AMPLIFY) Trial JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26627879 #FOAvip Background: In the Apixaban for the Initial Management of Pulmonary Embolism and Deep?Vein Thrombosis as First?Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism?related death, with significantly less bleeding. This analysis evaluated the effects of apixaban versus enoxaparin/warfarin on all?cause hospitalizations during AMPLIFY. Methods and Results: Of the 5365 patients included, 2676 received apixaban and 2689 received enoxaparin/warfarin. All?cause hospitalizations during the treatment period after the index event were captured using dedicated case report forms. Outcomes included all?cause hospitalizations and time from randomization to first hospitalization. Patients were censored at death, loss to follow?up, or end of study, whichever came first. Treatment effects were assessed using Cox proportional hazards regression models. During the treatment period after the index event, 343 patients were hospitalized at least once: 153 (5.72%) in the apixaban group and 190 (7.07%) in the enoxaparin/warfarin group. Compared with enoxaparin/warfarin, apixaban significantly reduced all?cause hospitalizations (hazard ratio 0.804, 95% CI=0.650?0.995, P=0.045). All?cause hospitalization rates within the first 30 days after the index event were 2.28% and 3.35% in the apixaban and enoxaparin/warfarin groups, respectively (hazard ratio 0.676, 95% CI=0.488?0.935, P=0.018). For all patients, the average per?patient estimated mean length of hospital stay was also shorter with apixaban than enoxaparin/warfarin (0.57 days versus 1.01 days, P<0.0001). Conclusions: Apixaban significantly reduced all?cause hospitalizations versus enoxaparin/warfarin, and shortened the length of hospital stay in patients with acute venous thromboembolism. Clinical Trial Registration: URL: https://Clinicaltrials.Gov/. Unique identifier: NCT00643201. Twit Text FOAVip Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First Line Therapy (AMPLIFY) Trial ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26627879 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26627879 #FOAvip English Wikipedia <ref>{{Cite pmid|26627879}}</ref> Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep?Vein Thrombosis as First?Line Therapy (AMPLIFY) Trial #MMPMID26627879 Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT J Am Heart Assoc 2015[Dec]; 4 (12): ä PMID26627879show ga Background: In the Apixaban for the Initial Management of Pulmonary Embolism and Deep?Vein Thrombosis as First?Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism?related death, with significantly less bleeding. This analysis evaluated the effects of apixaban versus enoxaparin/warfarin on all?cause hospitalizations during AMPLIFY. Methods and Results: Of the 5365 patients included, 2676 received apixaban and 2689 received enoxaparin/warfarin. All?cause hospitalizations during the treatment period after the index event were captured using dedicated case report forms. Outcomes included all?cause hospitalizations and time from randomization to first hospitalization. Patients were censored at death, loss to follow?up, or end of study, whichever came first. Treatment effects were assessed using Cox proportional hazards regression models. During the treatment period after the index event, 343 patients were hospitalized at least once: 153 (5.72%) in the apixaban group and 190 (7.07%) in the enoxaparin/warfarin group. Compared with enoxaparin/warfarin, apixaban significantly reduced all?cause hospitalizations (hazard ratio 0.804, 95% CI=0.650?0.995, P=0.045). All?cause hospitalization rates within the first 30 days after the index event were 2.28% and 3.35% in the apixaban and enoxaparin/warfarin groups, respectively (hazard ratio 0.676, 95% CI=0.488?0.935, P=0.018). For all patients, the average per?patient estimated mean length of hospital stay was also shorter with apixaban than enoxaparin/warfarin (0.57 days versus 1.01 days, P<0.0001). Conclusions: Apixaban significantly reduced all?cause hospitalizations versus enoxaparin/warfarin, and shortened the length of hospital stay in patients with acute venous thromboembolism. Clinical Trial Registration: URL: https://Clinicaltrials.Gov/. Unique identifier: NCT00643201. äApixaban Reduces Hospitalizations in Patients With Venous Thromboembol(epmc).pdf DeepDyve Pubget Overpricing